

**DRUG PRIOR AUTHORIZATION COMMITTEE**

**September 19, 2019**

**TENTATIVE AGENDA**

Harry S Truman Building  
301 W High St, Room 490-492  
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:25 - 10:35	DUR Update	Mark Roaseau

**Old Business**

10:35 – 10:45	<b>A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)</b> <ul style="list-style-type: none"><li>• <b>Multiple Sclerosis (MS) Agents</b></li></ul>	Josh Moore/ Mark Roaseau
---------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------

**New Business**

10:45 – 11:00	<b>B. Proposed Actions - New Drug/Product Review (See website and Attached Summary)</b> <ul style="list-style-type: none"><li>i. Open Access</li><li>ii. Clinical Edit/Step Therapy</li><li>iii. PDL Products</li><li>iv. Prior Authorization<ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ul>	Josh Moore/ Mark Roaseau
11:00 – 11:45	<b>C. Clinical Edits</b> <ul style="list-style-type: none"><li><b>I. BiDil Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>II. Botulinum Toxin Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>III. Diacomit Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>IV. Duchenne Muscular Dystrophy (DMD) Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ul>	

- V. Emsam Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- VI. Lambert-Eaton Myasthenic Syndrome(LEMS) Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- VII. Narcolepsy Inhibitors Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- VIII. Oxandrin Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- IX. Psychotropic Medications Polypharmacy Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- X. Ranexa Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- XI. SNRI Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- XII. SSRI Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- XIII. Synagis Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- XIV. Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- XV. Zolgensma Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision

**XVI. Zometa Clinical Edit**

- Discussion
- Public Hearing
- Decision

11:45 – 1:00 **D. Preferred Drug List (PDL)**

**I. ACE Inhibitors/Calcium Channel Blocker Combination Agents**

- Discussion
- Public Hearing
- Decision

**II. ACE Inhibitors and ACE Inhibitors Diuretic Combination Agents**

- Discussion
- Public Hearing
- Decision

**III. ADHD – Amphetamines – Short Acting Agents**

- Discussion
- Public Hearing
- Decision

**IV. ADHD – Methylphenidate – Long Acting Agents**

- Discussion
- Public Hearing
- Decision

**V. ADHD – Methylphenidate – Short Acting Agents**

- Discussion
- Public Hearing
- Decision

**VI. ADHD – Amphetamines – Long Acting Agents**

- Discussion
- Public Hearing
- Decision

**VII. ADHD – Non-stimulant Agents**

- Discussion
- Public Hearing
- Decision

**VIII. ARB and ARB Diuretic Combination Agents**

- Discussion
- Public Hearing
- Decision

**IX. Angiotensin II Receptor/Calcium Channel Blocker Combination Agents**

- Discussion
- Public Hearing
- Decision

- X. Anticoagulant Agents: Oral and Subcutaneous**
- Discussion
  - Public Hearing
  - Decision
- XI. Antiplatelet Agents**
- Discussion
  - Public Hearing
  - Decision
- XII. Beta Adrenergic Blocker and Beta Adrenergic Blocker Diuretic Combination Agents**
- Discussion
  - Public Hearing
  - Decision
- XIII. Calcium Channel Blocker Agents (Dihydropyridines)**
- Discussion
  - Public Hearing
  - Decision
- XIV. Calcium Channel Blocker Agents (Non-Dihydropyridines)**
- Discussion
  - Public Hearing
  - Decision
- XV. Direct Renin Inhibitors and Direct Renin Inhibitors Combination Agents**
- Discussion
  - Public Hearing
  - Decision
- XVI. Dry Eye Disease Agents - NEW**
- Discussion
  - Public Hearing
  - Decision
- XVII. Lipotropic Agents: Homozygous Familial Hypercholesterolemia Products**
- Discussion
  - Public Hearing
  - Decision
- XVIII. Lipotropic Agents: Niacin Derivatives**
- Discussion
  - Public Hearing
  - Decision
- XIX. Lipotropic Agents: Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors**
- Discussion
  - Public Hearing
  - Decision

- XX. Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products**
  - Discussion
  - Public Hearing
  - Decision
- XXI. Lipotropic Agents: Triglyceride Lowering Agents**
  - Discussion
  - Public Hearing
  - Decision
- XXII. Proton Pump Inhibitor Agents**
  - Discussion
  - Public Hearing
  - Decision
- XXIII. Pulmonary Arterial Hypertension (PHA) Agents: Inhaled/Injectable**
  - Discussion
  - Public Hearing
  - Decision
- XXIV. Pulmonary Arterial Hypertension (PHA) Agents: Oral Endothelin Receptor Antagonists (ETRAAs)**
  - Discussion
  - Public Hearing
  - Decision
- XXV. Pulmonary Arterial Hypertension (PHA) Agents: Oral Phosphodiesterase-5 (PDE5) Inhibitors and Soluble Guanylate Cyclase (SCG) Stimulators**
  - Discussion
  - Public Hearing
  - Decision
- XXVI. Pulmonary Arterial Hypertension (PHA) Agents: Oral Prostacyclin Pathway Agonists**
  - Discussion
  - Public Hearing
  - Decision
  -
- XXVII. Sympatholytic Antihypertensive Agents**
  - Discussion
  - Public Hearing
  - Decision

**E. Preferred Drug List Classes for Dec/Jan**

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

**LUNCH**

1:15-1:30

**Program Utilization Information - Conduent Update**

Luke Boehmer

1:30-1:50

**Other Business**

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly*

**NEXT MEETING: December 19, 2019**

MO Coalition for Community Behavioral Healthcare  
Lower Level CEO Room,  
221 Metro Drive, Jefferson City, MO